Combined with these, AML patients with dysregulation of SAT1, G6PD or CD44 may be sensitive to 8 drugs (ARRY-162, Cobimetinib, Mitomycin, lrofulven, Tamoxifen, Oxaliplatin, Fulvestrant and lmatinib). This evidence concerns the gene CD44 and acute myeloid leukemia.